304 related articles for article (PubMed ID: 33431577)
1. Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
Aoki S; Inoue K; Klein S; Halvorsen S; Chen J; Matsui A; Nikmaneshi MR; Kitahara S; Hato T; Chen X; Kawakubo K; Nia HT; Chen I; Schanne DH; Mamessier E; Shigeta K; Kikuchi H; Ramjiawan RR; Schmidt TC; Iwasaki M; Yau T; Hong TS; Quaas A; Plum PS; Dima S; Popescu I; Bardeesy N; Munn LL; Borad MJ; Sassi S; Jain RK; Zhu AX; Duda DG
Gut; 2022 Jan; 71(1):185-193. PubMed ID: 33431577
[TBL] [Abstract][Full Text] [Related]
2. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase.
Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R
Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870
[TBL] [Abstract][Full Text] [Related]
3. Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment.
Lin Y; Li B; Yang X; Cai Q; Liu W; Tian M; Luo H; Yin W; Song Y; Shi Y; He R
Neoplasia; 2019 Dec; 21(12):1133-1142. PubMed ID: 31759251
[TBL] [Abstract][Full Text] [Related]
4. Loss of liver-intestine cadherin in human intrahepatic cholangiocarcinoma promotes angiogenesis by up-regulating metal-responsive transcription factor-1 and placental growth factor.
Takamura M; Yamagiwa S; Wakai T; Tamura Y; Kamimura H; Kato T; Tsuchiya A; Matsuda Y; Shirai Y; Ichida T; Ajioka Y; Aoyagi Y
Int J Oncol; 2010 Jan; 36(1):245-54. PubMed ID: 19956853
[TBL] [Abstract][Full Text] [Related]
5. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma.
Cadamuro M; Brivio S; Mertens J; Vismara M; Moncsek A; Milani C; Fingas C; Cristina Malerba M; Nardo G; Dall'Olmo L; Milani E; Mariotti V; Stecca T; Massani M; Spirli C; Fiorotto R; Indraccolo S; Strazzabosco M; Fabris L
J Hepatol; 2019 Apr; 70(4):700-709. PubMed ID: 30553841
[TBL] [Abstract][Full Text] [Related]
6. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations.
Affo S; Nair A; Brundu F; Ravichandra A; Bhattacharjee S; Matsuda M; Chin L; Filliol A; Wen W; Song X; Decker A; Worley J; Caviglia JM; Yu L; Yin D; Saito Y; Savage T; Wells RG; Mack M; Zender L; Arpaia N; Remotti HE; Rabadan R; Sims P; Leblond AL; Weber A; Riener MO; Stockwell BR; Gaublomme J; Llovet JM; Kalluri R; Michalopoulos GK; Seki E; Sia D; Chen X; Califano A; Schwabe RF
Cancer Cell; 2021 Jun; 39(6):866-882.e11. PubMed ID: 33930309
[TBL] [Abstract][Full Text] [Related]
7. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
[TBL] [Abstract][Full Text] [Related]
8. Zinc Finger E-Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor-Stroma Paracrine Signaling.
Lobe C; Vallette M; Arbelaiz A; Gonzalez-Sanchez E; Izquierdo L; Pellat A; Guedj N; Louis C; Paradis V; Banales JM; Coulouarn C; Housset C; Vaquero J; Fouassier L
Hepatology; 2021 Dec; 74(6):3194-3212. PubMed ID: 34297412
[TBL] [Abstract][Full Text] [Related]
9. Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
Liu LZ; He YZ; Dong PP; Ma LJ; Wang ZC; Liu XY; Duan M; Yang LX; Shi JY; Zhou J; Fan J; Gao Q; Wang XY
Oncotarget; 2016 Nov; 7(46):75210-75220. PubMed ID: 27655691
[TBL] [Abstract][Full Text] [Related]
10. FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition.
Lv B; Ma L; Tang W; Huang P; Yang B; Wang L; Chen S; Gao Q; Zhang S; Xia J
Cell Physiol Biochem; 2018; 48(1):158-172. PubMed ID: 30001540
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II induces tumor progression and fibrosis in intrahepatic cholangiocarcinoma through an interaction with hepatic stellate cells.
Okamoto K; Tajima H; Ohta T; Nakanuma S; Hayashi H; Nakagawara H; Onishi I; Takamura H; Ninomiya I; Kitagawa H; Fushida S; Tani T; Fujimura T; Kayahara M; Harada S; Wakayama T; Iseki S
Int J Oncol; 2010 Nov; 37(5):1251-9. PubMed ID: 20878072
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the placental growth factor decreases burden of cholangiocarcinoma and hepatocellular carcinoma in a transgenic mouse model.
Heindryckx F; Bogaerts E; Coulon SH; Devlies H; Geerts AM; Libbrecht L; Stassen JM; Carmeliet P; Colle IO; Van Vlierberghe HR
Eur J Gastroenterol Hepatol; 2012 Sep; 24(9):1020-32. PubMed ID: 22772092
[TBL] [Abstract][Full Text] [Related]
13. Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma.
Ohira S; Sasaki M; Harada K; Sato Y; Zen Y; Isse K; Kozaka K; Ishikawa A; Oda K; Nimura Y; Nakanuma Y
Am J Pathol; 2006 Apr; 168(4):1155-68. PubMed ID: 16565491
[TBL] [Abstract][Full Text] [Related]
14. Isolation of cancer-associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma.
Sha M; Jeong S; Qiu BJ; Tong Y; Xia L; Xu N; Zhang JJ; Xia Q
Cancer Med; 2018 Sep; 7(9):4665-4677. PubMed ID: 30062820
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth.
Lepore A; Choy PM; Lee NCW; Carella MA; Favicchio R; Briones-Orta MA; Glaser SS; Alpini G; D'Santos C; Tooze RM; Lorger M; Syn WK; Papakyriakou A; Giamas G; Bubici C; Papa S
Hepatology; 2021 Nov; 74(5):2561-2579. PubMed ID: 34048060
[TBL] [Abstract][Full Text] [Related]
16. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated neutrophils and macrophages interaction contributes to intrahepatic cholangiocarcinoma progression by activating STAT3.
Zhou Z; Wang P; Sun R; Li J; Hu Z; Xin H; Luo C; Zhou J; Fan J; Zhou S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692217
[TBL] [Abstract][Full Text] [Related]
18. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.
Jin J; Ryu HS; Lee KB; Jang JJ
PLoS One; 2014; 9(2):e90247. PubMed ID: 24587299
[TBL] [Abstract][Full Text] [Related]
19. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma.
Wang J; Zhang K; Wang J; Wu X; Liu X; Li B; Zhu Y; Yu Y; Cheng Q; Hu Z; Guo C; Hu S; Mu B; Tsai CH; Li J; Smith L; Yang L; Liu Q; Chu P; Chang V; Zhang B; Wu M; Jiang X; Yen Y
Oncotarget; 2015 Aug; 6(22):18905-20. PubMed ID: 26056085
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of 14-3-3ΞΆ expression in intrahepatic cholangiocarcinoma and its clinical implications.
Zhang C; Liu LX; Dong ZR; Shi GM; Cai JB; Zhang PF; Ke AW; Yu JX; Zhou J; Fan J
Tumour Biol; 2015 Mar; 36(3):1781-9. PubMed ID: 25391422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
